Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Autor: Mezzanotte-Sharpe J; Vanderbilt University Medical Center., ONeill A; Dana-Farber Cancer Institute., Mayer IA; Vanderbilt University Medical Center., Arteaga CL; The University of Texas Southwestern Medical Center., Yang XJ; Northwestern University., Wagner LI; Wake Forest University., Cella D; Northwestern University., Meropol NJ; Case Western Reserve University., Alpaugh RK; Fox Chase Cancer Center., Saphner TJ; Aurora Health Care., Swaney RE; Denver Health Medical Center., Hoelzer KL; Memorial Healthcare System., Gradishar WJ; Northwestern University., Abramson VG; Vanderbilt University Medical Center., Sundaram PK; Columbus NCI Community Clinical Oncology Research Program., Jilani SZ; Good Samaritan Hospital., Perez EA; Mayo Clinic., Lin NU; Dana-Farber Cancer Institute., Jahanzeb M; University of Miami., Wolff AC; Johns Hopkins University., Sledge GW; Stanford Cancer Institute., Reid SA; Vanderbilt University Medical Center.

Publikováno v: Research square [Res Sq] 2024 Apr 29. Date of Electronic Publication: 2024 Apr 29.